Trials / Completed
CompletedNCT04012957
Desidustat in the Treatment of Anemia in CKD
A Phase 3, Multicenter, Multi-country, Open-label, Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Desidustat Versus Darbepoetin for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) Who Are Not on Dialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 588 (actual)
- Sponsor
- Zydus Lifesciences Limited · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who are not on dialysis. The study will be conducted over a period of up to 30 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desidustat Oral Tablet | Desidustat tablet |
| DRUG | Darbepoetin Alfa | Darbepoetin injection |
Timeline
- Start date
- 2019-07-20
- Primary completion
- 2021-08-25
- Completion
- 2021-08-25
- First posted
- 2019-07-09
- Last updated
- 2021-11-24
Locations
32 sites across 1 country: India
Source: ClinicalTrials.gov record NCT04012957. Inclusion in this directory is not an endorsement.